MME and hydrops fetalis: The PARAGON-HF trial of angiotensin receptor-neprilysin inhibitor (ARNI) did not present a significantly lower rate of hospitalization for HF and death from cardiovascular causes in patients with left ventricular ejection fraction (LVEF) ≥ 45%, but it suggested possible benefits among female patients as well as those with an LVEF ≤ 57% (3).